Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apratastat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 known ✓ | P78536 | 19/20 | 1.00 |
| ▸ | MMP13 known ✓ | P45452 | 19/20 | 1.00 |
| ▸ | MMP1 | P03956 | 20/20 | 1.00 |
| ▸ | MMP9 | P14780 | 4/20 | 1.00 |
| ▸ | MMP3 | P08254 | 3/20 | 1.00 |
| ▸ | ADAM10 | O14672 | 2/20 | 1.00 |
| ▸ | ADAM9 | Q13443 | 2/20 | 1.00 |
| ▸ | MMP2 | P08253 | 2/20 | 0.84 |
| ▸ | MMP7 | P09237 | 1/20 | 0.71 |
| ▸ | MMP8 | P22894 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apratastat SCHEMBL3946334 | 1.00 | MMP1 (1.00) | MMP1ADAM17MMP13MMP9MMP3 | |
| Apratastat SCHEMBL7430863 | 0.99 | MMP1 (0.98) | MMP1ADAM17MMP13MMP9MMP3 | |
| SCHEMBL3941060 | 0.95 | MMP1 (0.90) | MMP1ADAM17MMP13MMP9MMP3 | |
| SCHEMBL3944800 | 0.93 | MMP1 (1.00) | MMP1ADAM17MMP13MMP9MMP3 | |
| SCHEMBL12272230 | 0.93 | MMP1 (0.86) | MMP1ADAM17MMP13MMP9MMP3 | |
| SCHEMBL7325140 | 0.93 | MMP1 (0.86) | MMP1ADAM17MMP13MMP9MMP3 | |
| SCHEMBL7325752 | 0.93 | MMP1 (0.86) | MMP1ADAM17MMP13MMP9MMP3 | |
| SCHEMBL3941871 | 0.93 | MMP1 (0.86) | MMP1ADAM17MMP13MMP9MMP3 | |
| SCHEMBL3945436 | 0.92 | MMP1 (1.00) | MMP1ADAM17MMP13MMP9MMP3 | |
| SCHEMBL3948013 | 0.92 | MMP1 (0.85) | MMP1ADAM17MMP13MMP9MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 283 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12520839-B2 | Methods and compositions for cryopreservation of cell therapies | THE GEORGE WASHINGTON UNIVERSITY (US) | 2026-01-13 | — | — | US | claimed |
| US-20220394971-A1 | METHODS AND COMPOSITIONS FOR CRYOPRESERVATION OF CELL THERAPIES | THE GEORGE WASHINGTON UNIVERSITY | 2022-12-15 | — | — | US | claimed |
| US-20090137569-A1 | Administration of (3S)-N-hydroxy-4-(sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide or (S)-N_hydroxy-4-[4_(but-2-ynyloxy)phenylsulfonyl]-2,2-dimethyl thimomorpholine-3-carboxamide for preventing and/or treating inflammatory skin pathologies/afflictions | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-05-28 | — | — | US | claimed |
| US-7488754-B2 | Method for the treatment of polycystic kidney disease | WYETH (US) | 2009-02-10 | — | — | US | claimed |
| EP-1998779-A2 | USE OF (3S)-N-HYDROXY-4-({4-Ý(4-HYDROXY-2-BUTYNYL)OXY]PHENYL}SULFONYL)-2,2-DIMETHYL-3-THIOMORPHOLINE CARBOXAMIDE OR (S)-N-HYDROXY-4-(4-BUT-2-YNYLOXY-BENZENESULFONYL) -2,2-DIMETHYL-THIOMORPHOLINE -3-CARBOXAMIDE FOR TREATING INFLAMMATORY SKIN PATHOLOGIES | Galderma Research & Development, S.N.C. (FR) | 2008-12-10 | — | — | EP | claimed |
| US-7435732-B2 | Crystalline polymorphs of (3S)-N-hydroxy-4-({4-[-(4-hydroxy-2-butynyl)oxy]phenyl}sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide | WYETH (US) | 2008-10-14 | — | — | US | claimed |
| WO-2007107663-A2 | USE OF (3S)-N-HYDROXY-4-({4-[(4-HYDROXY-2-BUTYNYL)OXY]PHENYL}SULFONYL)-2,2-DIMETHYL-3-THIOMORPHOLINE CARBOXAMIDE OR (S)-N-HYDROXY-4-(4-BUT-2-YNYLOXY-BENZENESULFONYL) -2,2-DIMETHYL-THIOMORPHOLINE -3-CARBOXAMIDE FOR TREATING INFLAMMATORY SKIN PATHOLOGIES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-09-27 | — | — | WO | claimed |
| WO-2005123706-A9 | CRYSTALLINE POLYMORPHS OF (3S)-N-HYDROXY-4({4-[(4-HYDROXY-2-BUTYNYL)OXY]PHENYL}SULFONYL)-2,2-DIMETHYL-3-THIOMORPHOLINE CARBOXAMIDE | WYETH CORP (US) | 2006-04-27 | — | — | WO | claimed |
| WO-2005123706-A1 | CRYSTALLINE POLYMORPHS OF (3S)-N-HYDROXY-4({4-[(4-HYDROXY-2-BUTYNYL)OXY]PHENYL}SULFONYL)-2,2-DIMETHYL-3-THIOMORPHOLINE CARBOXAMIDE | WYETH (US) | 2005-12-29 | — | — | WO | claimed |
| US-20050272929-A1 | Crystalline polymorphs of (3S)-N-hydroxy-4-({4-[(4-hydroxy-2-butynul)oxy]phenyl}sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide | WYETH (US) | 2005-12-08 | — | — | US | claimed |
| EP-1144368-B1 | ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | WYETH CORP (US) | 2004-07-14 | — | — | EP | claimed |
| US-20040063672-A1 | Method for the treatment of polycystic kidney disease | WYETH HOLDINGS CORPORATION | 2004-04-01 | — | — | US | claimed |
| US-20040033988-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH (US) | 2004-02-19 | — | — | US | claimed |
| US-20030212049-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH (US) | 2003-11-13 | — | — | US | claimed |
| US-20030008849-A1 | Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors | LEVIN JEREMY I (US) | 2003-01-09 | — | — | US | claimed |
| WO-2002083112-A2 | METHOD FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | WYETH HOLDINGS CORPORATION (US) | 2002-10-24 | — | — | WO | claimed |
| EP-1144368-A2 | ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-17 | — | — | EP | claimed |
| US-6225311-B1 | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors | AMERICAN CYANAMID COMPANY | 2001-05-01 | — | — | US | claimed |
| WO-2000044709-A2 | ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | claimed |
| US-20260146040-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC (US) | 2026-05-28 | — | — | US | disclosed |
| WO-2026107349-A1 | HETEROCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASES | ANTARES THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260125375-A1 | SUBSTITUTED 1H-PYRAZOLO-PYRIDINE AND -PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12599664-B2 | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | NOVARTIS AG (CH) | 2026-04-14 | — | — | US | disclosed |
| US-12594333-B2 | Methods of treating inflammatory arthritis using IL-17 antagonists | NOVARTIS AG (CH) | 2026-04-07 | — | — | US | disclosed |
| EP-4116325-B1 | METHODS OF TREATING RHEUMATOID ARTHRITIS USING IL-17 ANTAGONISTS | NOVARTIS AG (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-20260083842-A1 | PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES | NOVARTIS AG (CH) | 2026-03-26 | — | — | US | disclosed |
| US-20260077042-A1 | METHODS OF TREATING PSORIATIC ARTHRITIS USING IL-17 ANTAGONISTS | NOVARTIS AG (CH) | 2026-03-19 | — | — | US | disclosed |
| EP-4695238-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4695262-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | Pfizer Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4688788-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | Pfizer Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12545684-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2026-02-10 | — | — | US | disclosed |
| US-12544438-B2 | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | NOVARTIS AG (CH) | 2026-02-10 | — | — | US | disclosed |
| US-12539304-B2 | Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor | PFIZER INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20260015665-A1 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML SCREENING LLC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12520839-B2 | Methods and compositions for cryopreservation of cell therapies | THE GEORGE WASHINGTON UNIVERSITY (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4667054-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| US-12491186-B2 | EGFR inhibitors for treating keratodermas | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2025-12-09 | — | — | US | disclosed |
| US-12485172-B2 | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | NOVARTIS AG (CH) | 2025-12-02 | — | — | US | disclosed |
| US-12485173-B2 | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | NOVARTIS AG (CH) | 2025-12-02 | — | — | US | disclosed |
| EP-4646416-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4646413-A1 | SOLID FORMS OF A CDK2 INHIBITOR | Blueprint Medicines Corporation (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4646414-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4646411-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12465635-B2 | Methods of treating inflammatory arthritis using secukinumab | NOVARTIS AG (CH) | 2025-11-11 | — | — | US | disclosed |
| US-12459945-B2 | Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents | Madera Therapeutics, LLC (US) | 2025-11-04 | — | — | US | disclosed |
| WO-2025227007-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | OHIO STATE INNOVATION FOUNDATION (US) | 2025-10-30 | — | — | WO | disclosed |
| WO-2025224249-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2025-10-30 | — | — | WO | disclosed |
| US-12447153-B2 | HER2 mutation inhibitors | PFIZER INC. (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2025202889-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2025-10-02 | — | — | WO | disclosed |
| EP-4417708-B1 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML SCREENING LLC (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20250295769-A1 | PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES | NOVARTIS AG (CH) | 2025-09-25 | — | — | US | disclosed |
| EP-4612154-A1 | REGULATORS OF PORPHYRIN AND INTERMEDIATES | Madera Therapeutics, LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250276062-A1 | PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES | NOVARTIS AG (CH) | 2025-09-04 | — | — | US | disclosed |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE LTD (SG) | 2025-09-04 | — | — | US | disclosed |
| US-20250279860-A1 | PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES | NOVARTIS AG (CH) | 2025-09-04 | — | — | US | disclosed |
| EP-3757126-B1 | METHODS OF TREATING PSORIATIC ARTHRITIS USING IL-17 ANTAGONISTS | NOVARTIS AG (CH) | 2025-09-03 | — | — | EP | disclosed |
| US-12378232-B2 | Cyclin dependent kinase inhibitors | PFIZER INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3880660-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| US-20250205332-A1 | METHODS OF TREATING PSORIATIC ARTHRITIS USING IL-17 ANTAGONISTS | NOVARTIS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| EP-4559935-A2 | PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES | Novartis AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| EP-4559934-A2 | PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES | Novartis AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| EP-4551296-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | Pfizer Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| US-12296008-B2 | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | NOVARTIS AG (CH) | 2025-05-13 | — | — | US | disclosed |
| WO-2025094035-A1 | TOLL-LIKE RECEPTOR AGONISTS AND CONJUGATES THEREOF | PFIZER INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-12281127-B2 | Pyrido[4,3-d]pyrimidine compounds | PFIZER INC. (US) | 2025-04-22 | — | — | US | disclosed |
| CN-113166065-B | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119768180-A | Coronavirus vaccines and methods of use | 生物技术欧洲股份公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-109715162-B | Protein kinase modulators | 南京盖特医药技术有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-114652816-B | Compositions containing HC-HA/PTX3 complexes and methods of use thereof | 生物组织控股公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20250074895-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | BLUEPRINT MEDICINES CORPORATION | 2025-03-06 | — | — | US | disclosed |
| EP-3912640-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING SECUKINUMAB | NOVARTIS AG (CH) | 2025-03-05 | — | — | EP | disclosed |
| US-12241125-B2 | Methods for assessing risk of developing a viral disease using a genetic test | PML SCREENING, LLC (US) | 2025-03-04 | — | — | US | disclosed |
| US-12234513-B2 | Methods for assessing risk of developing a viral disease using a genetic test | PML SCREENING, LLC (US) | 2025-02-25 | — | — | US | disclosed |
| EP-3784664-B1 | 2-AMINO-PYRIDINE OR 2-AMINO-PYRIMIDINE DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | PFIZER (US) | 2025-02-19 | — | — | EP | disclosed |
| US-12227807-B2 | Methods for assessing risk of developing a viral disease using a genetic test | PML SCREENING, LLC (US) | 2025-02-18 | — | — | US | disclosed |
| US-20250034173-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2025-01-30 | — | — | US | disclosed |
| US-20250000364-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | GLAS USA LLC | 2025-01-02 | — | — | US | disclosed |
| CN-113330000-B | 3-Carbonylamino-5-cyclopentyl-1 FI-pyrrole compounds having inhibitory activity on CDK2 | 辉瑞公司 | 2024-12-24 | — | — | CN | disclosed |
| US-20240415961-A1 | PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES | NOVARTIS AG (CH) | 2024-12-19 | — | — | US | disclosed |
| US-20240409573-A1 | CALICHEAMICIN DERIVATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2024-12-12 | — | — | US | disclosed |
| CN-119101012-A | Saturated heterocyclic compound, and preparation method and application thereof | 中国科学院上海药物研究所 | 2024-12-10 | — | — | CN | disclosed |
| US-20240391884-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-11-28 | — | — | US | disclosed |
| US-20240383902-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-11-21 | — | — | US | disclosed |
| CN-118873822-A | Treatment of gastrointestinal disorders with TNF inhibitors | 比奥拉治疗股份有限公司 | 2024-11-01 | — | — | CN | disclosed |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-10-31 | — | — | US | disclosed |
| US-20240352526-A1 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | THE ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP) (FR) | 2024-10-24 | — | — | US | disclosed |
| WO-2024218686-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024216154-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024213979-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024209339-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20240336631-A1 | Pyrido[4,3-d]pyrimidine Compounds | PFIZER INC. (US) | 2024-10-10 | — | — | US | disclosed |
| EP-4433470-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | Blueprint Medicines Corporation (US) | 2024-09-25 | — | — | EP | disclosed |
| US-12089916-B2 | Gastrointestinal tract detection methods, devices and systems | BIORA THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240301496-A1 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | THE ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP) (FR) | 2024-09-12 | — | — | US | disclosed |
| US-12084424-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2024-09-10 | — | — | US | disclosed |
| US-20240294506-A1 | CDK2 INHIBITORS | PFIZER INC. (US) | 2024-09-05 | — | — | US | disclosed |
| US-20240287040-A1 | SUBSTITUTED PYRIMIDINYL-PYRAZOLES AS CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-08-29 | — | — | US | disclosed |
| US-20240287611-A1 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | The Institut National de la Sante et de la Recherche Medicale (INSERM) (FR) | 2024-08-29 | — | — | US | disclosed |
| EP-4417708-A2 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML Screening, LLC (US) | 2024-08-21 | — | — | EP | disclosed |
| WO-2024168298-A1 | THE CDK2 INHIBITOR BLU-222 FOR TREATMENT OF CANCER | BLUEPRINT MEDICINES CORPORATION (US) | 2024-08-15 | — | — | WO | disclosed |
| EP-4410832-A2 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A TNF INHIBITOR | Biora Therapeutics, Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| US-12054778-B2 | Methods for assessing risk of developing a viral disease using a genetic test | PML SCREENING, LLC (US) | 2024-08-06 | — | — | US | disclosed |
| EP-4404960-A1 | CORONAVIRUS VACCINES AND METHODS OF USE | BioNTech SE (DE) | 2024-07-31 | — | — | EP | disclosed |
| EP-3554342-B1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A TNF INHIBITOR | BIORA THERAPEUTICS INC (US) | 2024-07-24 | — | — | EP | disclosed |
| WO-2024148087-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024148091-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024148089-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024148083-A1 | SOLID FORMS OF A CDK2 INHIBITOR | BLUEPRINT MEDICINES CORPORATION (US) | 2024-07-11 | — | — | WO | disclosed |
| CN-114364677-B | Imidazo [4,5-C ] pyridine derivatives as TOLL-like receptor agonists | 辉瑞公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118286225-A | 2-Amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors | 辉瑞公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20240173404-A1 | PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES | NOVARTIS AG (CH) | 2024-05-30 | — | — | US | disclosed |
| US-11993625-B2 | Calicheamicin derivatives and antibody drug conjugates thereof | PFIZER, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| WO-2024105563-A1 | SUBSTITUTED BICYCLIC PYRIDONE DERIVATIVES | PFIZER INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-4372005-A2 | PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES | Novartis AG (CH) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024097436-A1 | REGULATORS OF PORPHYRIN AND INTERMEDIATES | Madera Therapeutics, LLC (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-4177356-B1 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML SCREENING LLC (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-4363423-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2024-05-08 | — | — | EP | disclosed |
| US-11976064-B2 | Toll-like receptor agonists | PFIZER INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20240140947-A1 | COMPOUND FOR THE TREATMENT OF CANCER | PFIZER INC. (US) | 2024-05-02 | — | — | US | disclosed |
| EP-4359082-A1 | HER2 MUTATION INHIBITORS | Array BioPharma Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-11970498-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-04-30 | — | — | US | disclosed |
| CN-110430801-B | Treatment of gastrointestinal disorders with TNF inhibitors | 比奥拉治疗股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-112313219-B | 2-Amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors | 辉瑞公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4355742-A1 | SUBSTITUTED PYRIMIDINYL-PYRAZOLES AS CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2024-04-24 | — | — | EP | disclosed |
| US-20240124474-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2024-04-18 | — | — | US | disclosed |
| CN-117897384-A | CDK2 inhibitors | 缆图药品公司 | 2024-04-16 | — | — | CN | disclosed |
| WO-2024074977-A1 | SUBSTITUTED 1 H-PYRAZOLO-PYRIDINE AND-PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| EP-4349820-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| CN-117813300-A | Substituted pyrimidinyl-pyrazoles as CDK2 inhibitors | 缆图药品公司 | 2024-04-02 | — | — | CN | disclosed |
| US-11932648-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-03-19 | — | — | US | disclosed |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | disclosed |
| US-11913074-B2 | Methods for assessing risk of developing a viral disease using a genetic test | PML SCREENING, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| EP-3658539-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| CN-111094242-B | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| EP-3237001-B1 | PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES | NOVARTIS AG (CH) | 2024-02-07 | — | — | EP | disclosed |
| EP-3870261-B1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | BIORA THERAPEUTICS INC (US) | 2024-01-31 | — | — | EP | disclosed |
| EP-4309722-A2 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | Biora Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2024009191-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| WO-2024003773-A1 | 2,7-NAPHTHYRIDINE COMPOUNDS AS MASTL INHIBITORS | PFIZER INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| EP-3880659-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| EP-3880673-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| US-20230416211-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-12-28 | — | — | US | disclosed |
| EP-4291239-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE. LTD. (SG) | 2023-12-20 | — | — | EP | disclosed |
| CN-117209447-A | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-11834453-B2 | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-12-05 | — | — | US | disclosed |
| CN-117143042-A | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230346926-A1 | METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS | NOVARTIS AG (CH) | 2023-11-02 | — | — | US | disclosed |
| US-11801300-B2 | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | NOVARTIS AG (CH) | 2023-10-31 | — | — | US | disclosed |
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC | 2023-10-26 | — | — | US | disclosed |
| US-20230322791-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-10-12 | — | — | US | disclosed |
| US-20230312700-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A TNF INHIBITOR | GLAS USA LLC | 2023-10-05 | — | — | US | disclosed |
| EP-4252629-A2 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | Biora Therapeutics, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| US-11773082-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230293683-A1 | METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS | NOVARTIS AG (CH) | 2023-09-21 | — | — | US | disclosed |
| CN-116726361-A | Methods and devices for treating diseases with biologic therapeutic agents | 比奥拉治疗股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-116726362-A | Methods and devices for treating diseases with biologic therapeutic agents | 比奥拉治疗股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230279048-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2023-09-07 | — | — | US | disclosed |
| CN-111094243-B | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-4232146-A1 | METHODS OF TREATING AND PREDICTING NON-RESPONSE TO ANTI-TNF TREATMENT IN SUBJECTS WITH GASTROINTESTINAL TRACT DISEASES | Biora Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230265153-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD (GB) | 2023-08-24 | — | — | US | disclosed |
| US-20230265520-A1 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML SCREENING, LLC | 2023-08-24 | — | — | US | disclosed |
| US-11724992-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-15 | — | — | US | disclosed |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-08 | — | — | US | disclosed |
| US-11718603-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11707610-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | BIORA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| WO-2023092107-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | BLUEPRINT MEDICINES CORPORATION (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230159535-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-05-25 | — | — | US | disclosed |
| WO-2023092088-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | BLUEPRINT MEDICINES CORPORATION (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230149315-A1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | GLAS USA LLC | 2023-05-18 | — | — | US | disclosed |
| EP-4177356-A1 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML Screening, LLC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20230117684-A1 | COMBINATION OF AN ANAPLASTIC LYMPHOMA KINASE INHIBITOR AND A CYCLIN DEPENDENT KINASE INHIBITOR | PFIZER INC. (US) | 2023-04-20 | — | — | US | disclosed |
| CN-113348011-B | Method and apparatus for treating disease with biotherapeutic agents | 比奥拉治疗股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| WO-2023049272-A1 | CORONAVIRUS VACCINES AND METHODS OF USE | BIONTECH US INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| US-20230083931-A1 | CORONAVIRUS VACCINES AND METHODS OF USE | BIONTECH US INC. | 2023-03-16 | — | — | US | disclosed |
| US-20230079631-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-16 | — | — | US | disclosed |
| US-20230083005-A1 | METHODS OF KILLING OR INHIBITING THE GROWTH OF CANCER CELLS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2023-03-16 | — | — | US | disclosed |
| US-20230062815-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| US-20230041197-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNOMODULATOR | GLAS USA LLC | 2023-02-09 | — | — | US | disclosed |
| US-20230041385-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
| CN-115666704-A | Ingestible device for delivery of therapeutic agents to the gastrointestinal tract | 比奥拉治疗股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20230023414-A1 | METHODS AND DEVICES FOR TREATING A DISEASE WITH BIOTHERAPEUTICS | GLAS USA LLC | 2023-01-26 | — | — | US | disclosed |
| US-20230023851-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230011652-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-01-12 | — | — | US | disclosed |
| EP-4116325-A1 | METHODS OF TREATING RHEUMATOID ARTHRITIS USING IL-17 ANTAGONISTS | Novartis AG (CH) | 2023-01-11 | — | — | EP | disclosed |
| US-11547301-B2 | Methods for collecting and testing bacteria containing samples from within the gastrointestinal tract | BIORA THERAPEUTICS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11548928-B2 | Engineered platelets for targeted delivery of a therapeutic agent | JPV01 LTD. (GB) | 2023-01-10 | — | — | US | disclosed |
| WO-2023278326-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022269531-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-11534491-B2 | Methods of treating ankylosing spondylitis using IL-17 antagonists | NOVARTIS AG (CH) | 2022-12-27 | — | — | US | disclosed |
| WO-2022266190-A1 | SUBSTITUTED PYRIMIDINYL-PYRAZOLES AS CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-22 | — | — | WO | disclosed |
| EP-4103592-A1 | METHODS OF KILLING OR INHIBITING THE GROWTH OF CANCER CELLS | Tissuetech, Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20220394971-A1 | METHODS AND COMPOSITIONS FOR CRYOPRESERVATION OF CELL THERAPIES | THE GEORGE WASHINGTON UNIVERSITY | 2022-12-15 | — | — | US | disclosed |
| US-20220387397-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| US-11518796-B2 | Engineered platelets for targeted delivery of a therapeutic agent | JPV01 LTD. (GB) | 2022-12-06 | — | — | US | disclosed |
| US-11518782-B2 | Compositions containing HC-HA/PTX3 complexes and methods of use thereof | TISSUETECH, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| CN-115397841-A | Method of killing or inhibiting growth of cancer cells | 组织技术公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-111225662-B | Pharmaceutical compositions and dosage forms | 伊尼塔公司 | 2022-11-22 | — | — | CN | disclosed |
| EP-3625368-B1 | METHODS FOR ASSESSING THE RISK OF DEVELOPING PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY CAUSED BY JOHN CUNNINGHAM VIRUS BY GENETIC TESTING | PML SCREENING LLC (US) | 2022-11-09 | — | — | EP | disclosed |
| US-20220347306-A1 | SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS | AVELAS ACQUISITION CORPORATION | 2022-11-03 | — | — | US | disclosed |
| US-20220339169-A1 | METHODS OF TREATING OR SELECTING A TREATMENT FOR A SUBJECT RESISTANT TO TNF INHIBITOR USING A NLRP3 ANTAGONIST | IFM MANAGEMENT, INC. | 2022-10-27 | — | — | US | disclosed |
| US-20220340591-A1 | SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-10-27 | — | — | US | disclosed |
| US-11439802-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | BIORA THERAPEUTICS, INC. (US) | 2022-09-13 | — | — | US | disclosed |
| US-20220273196-A1 | INGESTIBLE DEVICE AND ASSOCIATED METHODS | GLAS USA LLC | 2022-09-01 | — | — | US | disclosed |
| US-20220274986-A1 | TOLL-LIKE RECEPTOR AGONISTS | PFIZER INC. (US) | 2022-09-01 | — | — | US | disclosed |
| US-20220267276-A1 | NLRP MODULATORS | NOVARTIS INFLAMMASOME RESEARCH, INC. | 2022-08-25 | — | — | US | disclosed |
| US-20220257592-A1 | METHODS OF TREATING CANCER | HOFFMANN-LA ROCHE INC. (US) | 2022-08-18 | — | — | US | disclosed |
| WO-2022173333-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE. LTD. (SG) | 2022-08-18 | — | — | WO | disclosed |
| US-20220249814-A1 | METHODS AND DEVICES FOR TREATING A DISEASE WITH BIOTHERAPEUTICS | GLAS USA LLC | 2022-08-11 | — | — | US | disclosed |
| US-20220251165-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-08-11 | — | — | US | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-20220227707-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-07-21 | — | — | US | disclosed |
| EP-4026898-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-07-13 | — | — | EP | disclosed |
| EP-3697758-B1 | SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-07-06 | — | — | EP | disclosed |
| US-11370763-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2022-06-28 | — | — | US | disclosed |
| CN-114652816-A | Compositions containing HC-HA/PTX3 complexes and methods of use thereof | 组织技术公司 | 2022-06-24 | — | — | CN | disclosed |
| US-20220193234-A1 | METHODS OF TREATING PSORIATIC ARTHRITIS USING IL-17 ANTAGONISTS | NOVARTIS AG (CH) | 2022-06-23 | — | — | US | disclosed |
| EP-4013404-A1 | METHODS OF TREATING CANCER | F. Hoffmann-La Roche AG (CH) | 2022-06-22 | — | — | EP | disclosed |
| WO-2022107054-A1 | INHIBITORS OF THE ADAM17 ENZYME AND COMPOSITIONS COMPRISING THEM FOR THE EFFECTIVE TREATMENT OF COVID-19 | CENTRO DE INVESTIGACIÓN Y DE ESTUDIOS AVANZADOS DEL INSTITUTO POLITÉCNICO NACIONAL (MX) | 2022-05-27 | — | — | WO | disclosed |
| EP-3999507-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS TOLL-LIKE RECEPTOR AGONISTS | Pfizer Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11339159-B2 | Toll-like receptor agonists | PFIZER INC. (US) | 2022-05-24 | — | — | US | disclosed |
| CN-114452380-A | Pharmaceutical product and stable liquid composition of IL-17 antibody | 诺华股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-114452381-A | Pharmaceutical product and stable liquid composition of IL-17 antibody | 诺华股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| WO-2022087313-A1 | METHODS OF TREATING AND PREDICTING NON-RESPONSE TO ANTI-TNF TREATMENT IN SUBJECTS WITH GASTROINTESTINAL TRACT DISEASES | PROGENITY, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| CN-109789144-B | Protein kinase modulators | 马德拉医疗公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-114364677-A | Imidazo [4,5-C ] pyridine derivatives as TOLL-like receptor agonists | 辉瑞公司 | 2022-04-15 | — | — | CN | disclosed |
| US-20220089580-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | PFIZER INC. (US) | 2022-03-24 | — | — | US | disclosed |
| US-20220089596-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC | 2022-03-24 | — | — | US | disclosed |
| CN-114222576-A | Methods of treating cancer | F·霍夫曼-罗氏股份公司 | 2022-03-22 | — | — | CN | disclosed |
| US-11253515-B2 | Pharmaceutical compositions and dosage forms | IGNYTA, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| CN-104619352-B | Compositions containing HC-HA/PTX3 complexes and methods of use thereof | 组织技术公司 | 2022-02-18 | — | — | CN | disclosed |
| US-20220041684-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-02-10 | — | — | US | disclosed |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| US-20210393632-A1 | EGFR INHIBITORS FOR TREATING KERATODERMAS | UNIVERSITÉ PARIS CITÉ (FR) | 2021-12-23 | — | — | US | disclosed |
| US-20200376013-A1 | SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE | AVELAS BIOSCIENCES, INC. | 2020-12-03 | — | — | US | disclosed |
| US-10040821-B2 | Compositions containing HC-HA/PTX3 complexes and methods of use thereof | TISSUETECH, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-9371367-B1 | Selective delivery molecules and methods of use | AVELAS BIOSCIENCES, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9278144-B2 | Selective delivery molecules and methods of use | AVELAS BIOSCIENCES, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150166624-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | TISSUETECH, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-20140005096-A1 | METHODS OF TREATING INFLAMMATION | CAROLUS THERAPEUTICS, INC. (US) | 2014-01-02 | — | — | US | disclosed |
| US-20100168089-A1 | UTILIZATION OF TACE INHIBITORS FOR THE TREATMENT OF ACNE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-07-01 | — | — | US | disclosed |
| EP-2160606-A2 | TACE INHIBITORS IN THE TREATMENT OF ACNE | Galderma Research & Development (FR) | 2010-03-10 | — | — | EP | disclosed |
| US-20090137569-A1 | Administration of (3S)-N-hydroxy-4-(sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide or (S)-N_hydroxy-4-[4_(but-2-ynyloxy)phenylsulfonyl]-2,2-dimethyl thimomorpholine-3-carboxamide for preventing and/or treating inflammatory skin pathologies/afflictions | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-05-28 | — | — | US | disclosed |
| US-7488754-B2 | Method for the treatment of polycystic kidney disease | WYETH (US) | 2009-02-10 | — | — | US | disclosed |
| WO-2009004247-A2 | TACE INHIBITORS IN THE TREATMENT OF ACNE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-01-08 | — | — | WO | disclosed |
| EP-1998779-A2 | USE OF (3S)-N-HYDROXY-4-({4-Ý(4-HYDROXY-2-BUTYNYL)OXY]PHENYL}SULFONYL)-2,2-DIMETHYL-3-THIOMORPHOLINE CARBOXAMIDE OR (S)-N-HYDROXY-4-(4-BUT-2-YNYLOXY-BENZENESULFONYL) -2,2-DIMETHYL-THIOMORPHOLINE -3-CARBOXAMIDE FOR TREATING INFLAMMATORY SKIN PATHOLOGIES | Galderma Research & Development, S.N.C. (FR) | 2008-12-10 | — | — | EP | disclosed |
| EP-1998779-A2 | USE OF (3S)-N-HYDROXY-4-({4-Ý(4-HYDROXY-2-BUTYNYL)OXY]PHENYL}SULFONYL)-2,2-DIMETHYL-3-THIOMORPHOLINE CARBOXAMIDE OR (S)-N-HYDROXY-4-(4-BUT-2-YNYLOXY-BENZENESULFONYL) -2,2-DIMETHYL-THIOMORPHOLINE -3-CARBOXAMIDE FOR TREATING INFLAMMATORY SKIN PATHOLOGIES | Galderma Research & Development, S.N.C. (FR) | 2008-12-10 | — | — | EP | disclosed |
| US-7435732-B2 | Crystalline polymorphs of (3S)-N-hydroxy-4-({4-[-(4-hydroxy-2-butynyl)oxy]phenyl}sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide | WYETH (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435732-B2 | Crystalline polymorphs of (3S)-N-hydroxy-4-({4-[-(4-hydroxy-2-butynyl)oxy]phenyl}sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide | WYETH (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435732-B2 | Crystalline polymorphs of (3S)-N-hydroxy-4-({4-[-(4-hydroxy-2-butynyl)oxy]phenyl}sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide | WYETH (US) | 2008-10-14 | — | — | US | disclosed |
| US-7402414-B2 | Enzymatic process for deacetylation of a phenoxy-alkynyl acetate to the corresponding alcohol | WYETH (US) | 2008-07-22 | — | — | US | disclosed |
| US-7402414-B2 | Enzymatic process for deacetylation of a phenoxy-alkynyl acetate to the corresponding alcohol | WYETH (US) | 2008-07-22 | — | — | US | disclosed |
| WO-2007107663-A3 | USE OF (3S)-N-HYDROXY-4-({4-[(4-HYDROXY-2-BUTYNYL)OXY]PHENYL}SULFONYL)-2,2-DIMETHYL-3-THIOMORPHOLINE CARBOXAMIDE OR (S)-N-HYDROXY-4-(4-BUT-2-YNYLOXY-BENZENESULFONYL) -2,2-DIMETHYL-THIOMORPHOLINE -3-CARBOXAMIDE FOR TREATING INFLAMMATORY SKIN PATHOLOGIES | GALDERMA RES & DEV (FR) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007107663-A2 | USE OF (3S)-N-HYDROXY-4-({4-[(4-HYDROXY-2-BUTYNYL)OXY]PHENYL}SULFONYL)-2,2-DIMETHYL-3-THIOMORPHOLINE CARBOXAMIDE OR (S)-N-HYDROXY-4-(4-BUT-2-YNYLOXY-BENZENESULFONYL) -2,2-DIMETHYL-THIOMORPHOLINE -3-CARBOXAMIDE FOR TREATING INFLAMMATORY SKIN PATHOLOGIES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107663-A2 | USE OF (3S)-N-HYDROXY-4-({4-[(4-HYDROXY-2-BUTYNYL)OXY]PHENYL}SULFONYL)-2,2-DIMETHYL-3-THIOMORPHOLINE CARBOXAMIDE OR (S)-N-HYDROXY-4-(4-BUT-2-YNYLOXY-BENZENESULFONYL) -2,2-DIMETHYL-THIOMORPHOLINE -3-CARBOXAMIDE FOR TREATING INFLAMMATORY SKIN PATHOLOGIES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-09-27 | — | — | WO | disclosed |
| EP-1796727-A2 | METHOD FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | Wyeth a Corporation of the State of Delaware (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2005123706-A9 | CRYSTALLINE POLYMORPHS OF (3S)-N-HYDROXY-4({4-[(4-HYDROXY-2-BUTYNYL)OXY]PHENYL}SULFONYL)-2,2-DIMETHYL-3-THIOMORPHOLINE CARBOXAMIDE | WYETH CORP (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2005123706-A9 | CRYSTALLINE POLYMORPHS OF (3S)-N-HYDROXY-4({4-[(4-HYDROXY-2-BUTYNYL)OXY]PHENYL}SULFONYL)-2,2-DIMETHYL-3-THIOMORPHOLINE CARBOXAMIDE | WYETH CORP (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006042100-A2 | METHOD FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | WYETH (US) | 2006-04-20 | — | — | WO | disclosed |
| US-20060079515-A1 | Method for the treatment of polycystic kidney disease | WYETH (US) | 2006-04-13 | — | — | US | disclosed |
| WO-2005123706-A1 | CRYSTALLINE POLYMORPHS OF (3S)-N-HYDROXY-4({4-[(4-HYDROXY-2-BUTYNYL)OXY]PHENYL}SULFONYL)-2,2-DIMETHYL-3-THIOMORPHOLINE CARBOXAMIDE | WYETH (US) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005123706-A1 | CRYSTALLINE POLYMORPHS OF (3S)-N-HYDROXY-4({4-[(4-HYDROXY-2-BUTYNYL)OXY]PHENYL}SULFONYL)-2,2-DIMETHYL-3-THIOMORPHOLINE CARBOXAMIDE | WYETH (US) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005123933-A1 | ENZYMATIC DEACETYLATION OF A PHENOXY-ALKYNYL ACETATE | WYETH (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050272929-A1 | Crystalline polymorphs of (3S)-N-hydroxy-4-({4-[(4-hydroxy-2-butynul)oxy]phenyl}sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide | WYETH (US) | 2005-12-08 | — | — | US | disclosed |
| US-20050272929-A1 | Crystalline polymorphs of (3S)-N-hydroxy-4-({4-[(4-hydroxy-2-butynul)oxy]phenyl}sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide | WYETH (US) | 2005-12-08 | — | — | US | disclosed |
| US-20050272725-A1 | Enzymatic process for deacetylation of a phenoxy-alkynyl acetate to the corresponding alcohol | WYETH (US) | 2005-12-08 | — | — | US | disclosed |
| US-20050113346-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH HOLDINGS CORPORATION | 2005-05-26 | — | — | US | disclosed |
| US-6812227-B2 | SULFUR COMPOUNDS SUCH AS 2-((4-BUT-2-YNYLOXY-BENZENESULFONYL)-METHYL-AMINO)-N-HYDROXY-3-METHYL -BUTYRAMIDE, USED AS TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME (TACE) INHIBITORS, FOR PROPHYLAXIS OF RHEUMATIC DISEASES, SEPSIS OR INFLAMMATION | WYETH HOLDINGS CORPORATION | 2004-11-02 | — | — | US | disclosed |
| EP-1144368-B1 | ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | WYETH CORP (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6716833-B2 | RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, SEPSIS, AIDS, ULCERATIVE COLITIS, MULTIPLE SCLEROSIS, CROHN'S DISEASE AND DEGENERATIVE CARTILAGE LOSS. | WYETH HOLDINGS CORPORATION | 2004-04-06 | — | — | US | disclosed |
| US-20040063672-A1 | Method for the treatment of polycystic kidney disease | WYETH HOLDINGS CORPORATION | 2004-04-01 | — | — | US | disclosed |
| US-20040033988-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH (US) | 2004-02-19 | — | — | US | disclosed |
| US-20030212049-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH (US) | 2003-11-13 | — | — | US | disclosed |
| US-20030008849-A1 | Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors | LEVIN JEREMY I (US) | 2003-01-09 | — | — | US | disclosed |
| WO-2002083112-A2 | METHOD FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | WYETH HOLDINGS CORPORATION (US) | 2002-10-24 | — | — | WO | disclosed |
| EP-1144368-A2 | ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-17 | — | — | EP | disclosed |
| US-6225311-B1 | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors | AMERICAN CYANAMID COMPANY | 2001-05-01 | — | — | US | disclosed |
| WO-2000044709-A2 | ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000044709-A2 | ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063672-A1 | Method for the treatment of polycystic kidney disease | PKD1, PKD2, PCSK6 | ADAM17 9/4885MMP13 246/4885MMP1 215/4885 |
| US-20230062815-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | ADAM17 3347/4885MMP13 1631/4885MMP1 2516/4885 |
| US-20030008849-A1 | Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | ADAM17 29/4885MMP13 114/4885MMP1 130/4885 |
| US-20220347306-A1 | SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS | PAICS, TIE1, ANTXR2 | ADAM17 921/4885MMP13 375/4885MMP1 425/4885 |
| US-11707610-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | MUC1, SLC10A2, FABP2 | ADAM17 1095/4885MMP13 232/4885MMP1 16/4885 |
| US-12089916-B2 | Gastrointestinal tract detection methods, devices and systems | FABP2, SI, MLNR | ADAM17 2475/4885MMP13 1889/4885MMP1 2480/4885 |
| US-20240140947-A1 | COMPOUND FOR THE TREATMENT OF CANCER | TP53, MCL1, FGFR4 | ADAM17 1939/4885MMP13 4549/4885MMP1 4201/4885 |
| US-20260015665-A1 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | CD59, MASP2, CD58 | ADAM17 3692/4885MMP13 2035/4885MMP1 1469/4885 |
| US-20040033988-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | ADAM17 29/4885MMP13 114/4885MMP1 130/4885 |
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | ADAM17 3347/4885MMP13 1631/4885MMP1 2516/4885 |
| US-20260077042-A1 | METHODS OF TREATING PSORIATIC ARTHRITIS USING IL-17 ANTAGONISTS | IL17A, HLA-DRB1, IL15 | ADAM17 621/4885MMP13 161/4885MMP1 384/4885 |
| US-20240409573-A1 | CALICHEAMICIN DERIVATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | STT3A, CLSPN, STT3B | ADAM17 477/4885MMP13 1416/4885MMP1 3700/4885 |
| US-20230079631-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | ADAM17 3347/4885MMP13 1631/4885MMP1 2516/4885 |
| US-11976064-B2 | Toll-like receptor agonists | TLR3, TLR1, TLR4 | ADAM17 2868/4885MMP13 3447/4885MMP1 4422/4885 |
| US-11932648-B2 | CDK2 inhibitors | CDK2, CDK20, CDK2AP1 | ADAM17 2919/4885MMP13 3145/4885MMP1 3868/4885 |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | ADAM17 3135/4885MMP13 1607/4885MMP1 2511/4885 |
| US-20230023414-A1 | METHODS AND DEVICES FOR TREATING A DISEASE WITH BIOTHERAPEUTICS | HAVCR2, CD47, FCGR3B | ADAM17 302/4885MMP13 240/4885MMP1 532/4885 |
| US-20260083842-A1 | PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES | IL17A, RAB7A, IL15 | ADAM17 696/4885MMP13 534/4885MMP1 1732/4885 |
| US-20090137569-A1 | Administration of (3S)-N-hydroxy-4-(sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide or (S)-N_hydroxy-4-[4_(but-2-ynyloxy)phenylsulfonyl]-2,2-dimethyl thimomorpholine-3-carboxamide for preventing and/or treating inflammatory skin pathologies/afflictions | HRH4, HRH3, HRH2 | ADAM17 3485/4885MMP13 326/4885MMP1 943/4885 |
| US-12544438-B2 | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | IL17A, IL15, STK17A | ADAM17 892/4885MMP13 3101/4885MMP1 3154/4885 |
| US-20060079515-A1 | Method for the treatment of polycystic kidney disease | ERBB2, PKD2, EGFR | ADAM17 19/4885MMP13 458/4885MMP1 478/4885 |
| US-20230322791-A1 | CDK2 INHIBITORS | CDK2, CDK20, CDK2AP1 | ADAM17 2919/4885MMP13 3145/4885MMP1 3868/4885 |
| US-20240287040-A1 | SUBSTITUTED PYRIMIDINYL-PYRAZOLES AS CDK2 INHIBITORS | CDK2, CCNI, CDK20 | ADAM17 3151/4885MMP13 3501/4885MMP1 4074/4885 |
| US-20230117684-A1 | COMBINATION OF AN ANAPLASTIC LYMPHOMA KINASE INHIBITOR AND A CYCLIN DEPENDENT KINASE INHIBITOR | CDK4, CDK2, CDK6 | ADAM17 3230/4885MMP13 1639/4885MMP1 1685/4885 |
| US-20030212049-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | ADAM17 29/4885MMP13 114/4885MMP1 130/4885 |
| US-12599664-B2 | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | IL17A, IL15, IL5 | ADAM17 461/4885MMP13 2007/4885MMP1 2294/4885 |
| US-20220387397-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | ADAM17 3305/4885MMP13 1579/4885MMP1 2322/4885 |
| US-20220339169-A1 | METHODS OF TREATING OR SELECTING A TREATMENT FOR A SUBJECT RESISTANT TO TNF INHIBITOR USING A NLRP3 ANTAGONIST | NLRP3, NLRP1, TNF | ADAM17 543/4885MMP13 301/4885MMP1 1409/4885 |
| US-20250074895-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | CDK2, CDK20, CDK2AP1 | ADAM17 3028/4885MMP13 3802/4885MMP1 4030/4885 |
| US-20220340591-A1 | SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | ADAM17 3188/4885MMP13 3738/4885MMP1 2449/4885 |
| US-20230041385-A1 | HER2 MUTATION INHIBITORS | ERBB2, EGFR, ERBB3 | ADAM17 1729/4885MMP13 4393/4885MMP1 4149/4885 |
| US-20210393632-A1 | EGFR INHIBITORS FOR TREATING KERATODERMAS | MAP3K3, GRK3, TAS1R3 | ADAM17 4276/4885MMP13 1934/4885MMP1 3199/4885 |
| US-20230041197-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNOMODULATOR | FABP2, IL2, TSLP | ADAM17 3648/4885MMP13 1721/4885MMP1 2212/4885 |
| US-11834453-B2 | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors | ERBB2, EGFR, ERBB3 | ADAM17 2250/4885MMP13 4500/4885MMP1 4342/4885 |
| US-20230011652-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | ADAM17 3367/4885MMP13 1698/4885MMP1 2613/4885 |
| US-20240336631-A1 | Pyrido[4,3-d]pyrimidine Compounds | DPYD, PNPO, TYMP | ADAM17 4436/4885MMP13 4336/4885MMP1 4488/4885 |
| US-20200376013-A1 | SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE | ABCG2, CD44, PITRM1 | ADAM17 56/4885MMP13 986/4885MMP1 146/4885 |
| US-20260125375-A1 | SUBSTITUTED 1H-PYRAZOLO-PYRIDINE AND -PYRIMIDINE COMPOUNDS | CCR1, CCR6, CCRL2 | ADAM17 4874/4885MMP13 4620/4885MMP1 4432/4885 |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | ADAM17 3188/4885MMP13 3738/4885MMP1 2449/4885 |
| US-20100168089-A1 | UTILIZATION OF TACE INHIBITORS FOR THE TREATMENT OF ACNE | MMP17, MMP25, TIMP3 | ADAM17 11/4885MMP13 18/4885MMP1 16/4885 |
| US-20240124474-A1 | HER2 MUTATION INHIBITORS | ERBB2, EGFR, ERBB3 | ADAM17 1519/4885MMP13 4080/4885MMP1 3521/4885 |
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | ADAM17 2953/4885MMP13 3192/4885MMP1 3548/4885 |
| US-11993625-B2 | Calicheamicin derivatives and antibody drug conjugates thereof | STT3A, CLSPN, STT3B | ADAM17 477/4885MMP13 1416/4885MMP1 3700/4885 |
| US-20260146040-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | CTRB1, CTRB2, CPN1 | ADAM17 545/4885MMP13 26/4885MMP1 35/4885 |
| US-11773082-B2 | CDK2 inhibitors | CDK2, CDK1, CCNI | ADAM17 2881/4885MMP13 3800/4885MMP1 3899/4885 |
| US-12378232-B2 | Cyclin dependent kinase inhibitors | CCNY, CCNI, CCNK | ADAM17 4061/4885MMP13 1392/4885MMP1 2455/4885 |
| US-12084424-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | ADAM17 3347/4885MMP13 1631/4885MMP1 2516/4885 |
| US-12491186-B2 | EGFR inhibitors for treating keratodermas | MAP3K3, GRK3, TAS1R3 | ADAM17 4276/4885MMP13 1934/4885MMP1 3199/4885 |
| US-11724992-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | ADAM17 3347/4885MMP13 1631/4885MMP1 2516/4885 |
| US-11718603-B2 | CDK2 inhibitors | CDK2, CDK1, CCNI | ADAM17 2881/4885MMP13 3800/4885MMP1 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.